Savior Lifetec Corporation announced that it is signed a sales contract with Shenzhen China Resources GOSUN Pharmaceuticals, authorizing the company to exclusively sell the company's ertapenem injection products in the mainland market. Effect on company finances and business: Accelerating the introduction of ertapenem into the Chinese mainland market will help increase the global market share of the company's products. Concrete purpose/objective: Through this cooperation project, the company will open a new milestone in the company's mainland market sales.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23 TWD | +0.66% | +5.50% | +2.45% |
1st Jan change | Capi. | |
---|---|---|
+2.45% | 22Cr | |
+22.69% | 4.38TCr | |
+25.56% | 2.3TCr | |
+18.00% | 1.53TCr | |
+8.91% | 1.37TCr | |
+42.72% | 1.2TCr | |
-7.49% | 697.64Cr | |
-0.05% | 678.76Cr | |
-8.87% | 572.55Cr | |
+12.22% | 559.02Cr |
- Stock Market
- Equities
- 4167 Stock
- News Savior Lifetec Corporation
- Savior Lifetec Corporation and Shenzhen China Resources Gosun Pharmaceutical Co.,Ltd Signs Exclusive Sales Contract for Ertapenem in the Mainland Market